– Enable Injections, Inc. (“Enable”), a leader in wearable drug delivery technology, today announced an expanded partnership with Roche.
– The collaboration leverages Enable’s expertise in the enFuse® platform to accelerate the development and commercialization of innovative treatment options.
EnFuse Technology: Revolutionizing Drug Delivery
The enFuse platform is a groundbreaking wearable device designed for:
- Subcutaneous Delivery of Large Volumes: Unlike traditional methods, enFuse delivers large volumes of medication subcutaneously, eliminating the need for intravenous (IV) administration.
- Simplified Treatment Experience: enFuse offers a simpler and potentially more comfortable injection experience for patients compared to IV treatments.
Roche Gains Exclusive Rights to Combine enFuse with Specific Molecules
Under the terms of the agreement, Roche receives a worldwide, exclusive license to develop and commercialize combinations of the enFuse technology with specific drugs from their portfolio. Enable will take responsibility for the clinical and commercial manufacturing and supply of the enFuse system.
“IV infusions can be inconvenient and time-consuming for both patients and providers. This is especially true when treating chronic disorders, which require longer-term treatment and frequent trips to the clinic,” said Mike Hooven, Chairman and CEO of Enable Injections. “enFuse was designed to overcome IV infusion shortcomings through fast, simple and convenient delivery, bringing efficiency and value to the entire spectrum of healthcare, including patients, providers, and payers, with the ability for at home self-administration.”
